Tourmaline Bio, Inc.
TRMLDelisted Oct 28, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001827506
Tourmaline Bio, Inc. was delisted on Oct 28, 2025; its insiders filed their last Form 4 on Oct 28, 2025; 134 institutions reported holding it in 13F filings for Q3 2025, worth $1.03B in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:32 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 13, 2025 | Jan 24, 2024 | Feb 16, 2023 | Mar 17, 2022 |
| Operating expenses | $89.7M | $45.4M | $76.5M | $47.5M |
| Research and development | $67.0M | $32.4M | $57.0M | $34.2M |
| Selling, general and administrative | $22.7M | $13.0M | $19.5M | $13.3M |
| Operating income | -$89.7M | -$45.4M | -$76.5M | -$47.5M |
| Income tax | $0 | $0 | $0 | $0 |
| Net income | -$73.2M | -$42.1M | -$73.9M | -$47.8M |
| EPS, basic | $-2.89 | $-8.87 | $-1.79 | – |
| EPS, diluted | $-2.89 | $-8.87 | $-1.79 | – |
| Weighted shares, basic | 25.3M | 4.75M | 41.2M | – |
| Weighted shares, diluted | 25.3M | 4.75M | 41.2M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 13, 2025 | Jan 24, 2024 | Feb 16, 2023 | Mar 17, 2022 |
| Cash and equivalents | $30.5M | $140.7M | $13.7M | $18.6M |
| Short-term investments | – | – | $167.6M | $225.4M |
| Total current assets | $268.8M | $208.9M | $185.6M | $246.5M |
| Property, plant and equipment | $55.0K | $85.0K | $5.35M | $4.80M |
| Total assets | $309.0M | $210.3M | $193.7M | $251.4M |
| Accounts payable | $3.58M | $1.07M | $3.89M | $2.56M |
| Total current liabilities | $8.91M | $5.00M | $11.5M | $7.99M |
| Total liabilities | $8.95M | $5.25M | $13.7M | $8.61M |
| Shareholders' equity | $300.1M | $205.0M | $180.1M | $242.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 13, 2025 | Jan 24, 2024 | Feb 16, 2023 | Mar 17, 2022 |
| Operating cash flow | -$77.3M | -$28.1M | -$60.9M | -$40.0M |
| Capital expenditures | $9.00K | $56.0K | $3.04M | $2.44M |
| Free cash flow | -$77.3M | -$28.1M | -$63.9M | -$42.4M |
| Depreciation and amortization | – | – | $1.38M | $623.0K |
| Stock-based compensation | $6.59M | $5.77M | $11.2M | $3.78M |
| Share buybacks | $4.00K | – | – | – |
| Investing cash flow | -$194.3M | $3.84M | $55.7M | -$96.4M |
| Financing cash flow | $161.3M | $156.7M | $242.0K | $137.4M |
| Net change in cash | -$110.2M | $132.5M | -$4.94M | $1.02M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 1, 2025 | 25.7M | +0.2% | SEC |
| Apr 25, 2025 | 25.7M | +0.2% | SEC |
| Mar 7, 2025 | 25.7M | +0.2% | SEC |
| Nov 1, 2024 | 25.6M | +26.1% | SEC |
| Aug 2, 2024 | 25.6M | −40.0% | SEC |
| May 10, 2024 | 25.6M | −39.2% | SEC |
| Mar 15, 2024 | 25.6M | −39.0% | SEC |
| Nov 10, 2023 | 20.3M | −51.3% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.